The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

Abstract excerpt

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive primary liver tumor with increasing incidence worldwide, dismal prognosis, and few therapeutic options. Mounting evidence underlines the role of the Hippo pathway in this disease; however, the molecular mechanisms whereby the Hippo cascade contributes to cholangiocarcinogenesis remain poorly defined. METHODS: We established novel iCCA mouse...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholangiocarcinoma and Gallbladder Cancer Studies
• Share to Hippo pathway signaling and YAP/TAZ
• Share to Liver physiology and pathology